Efficient development and usability testing of decision support interventions for older women with breast cancer.
breast cancer
decision support
older patients
patient decision aids
shared decision-making
Journal
Patient preference and adherence
ISSN: 1177-889X
Titre abrégé: Patient Prefer Adherence
Pays: New Zealand
ID NLM: 101475748
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
26
1
2019
pubmed:
27
1
2019
medline:
27
1
2019
Statut:
epublish
Résumé
Around one-third of breast cancers diagnosed every year in the UK are in women aged ≥70 years. However, there are currently no decision support interventions (DESIs) for older women who have a choice between primary endocrine therapy and surgery followed by adjuvant endocrine therapy (surgery+endocrine therapy), or who can choose whether or not to have chemotherapy following surgery. There is also little evidence-based guidance specifically on the management of these older patients. A large UK cohort study is currently underway to address this lack of evidence and to develop two DESIs to facilitate shared decision-making with older women about breast cancer treatments. Here, we present the development and initial testing of these two DESIs. An initial prototype DESI was developed for the choice of primary endocrine therapy or surgery+endocrine therapy. Semi-structured interviews with healthy volunteers and patients explored DESI acceptability, usability, and utility. A framework approach was used for analysis. A second DESI for the choice of having chemotherapy or not was subsequently developed based on more focused development and testing. Participants (n=22, aged 75-94 years, 64% healthy volunteers, 36% patients) found the primary endocrine therapy /surgery+endocrine therapy DESI acceptable, and contributed to improved wording and illustrations to address misunderstandings. The chemotherapy DESI (tested with 14 participants, aged 70-87 years, 57% healthy volunteers, 43% patients) was mostly understandable, however, suggestions for rewording sections were made. Most participants considered the DESIs helpful, but highlighted the importance of complementary discussions with clinicians. It was possible to use a template DESI to efficiently create a second prototype for a different treatment option (chemotherapy). Both DESIs were acceptable and considered helpful to support/augment consultations. Development of acceptable additional DESIs for similar target populations using simplified methods may be an efficient way to develop future DESIs. Further research is needed to test the effectiveness of the DESIs.
Sections du résumé
BACKGROUND
BACKGROUND
Around one-third of breast cancers diagnosed every year in the UK are in women aged ≥70 years. However, there are currently no decision support interventions (DESIs) for older women who have a choice between primary endocrine therapy and surgery followed by adjuvant endocrine therapy (surgery+endocrine therapy), or who can choose whether or not to have chemotherapy following surgery. There is also little evidence-based guidance specifically on the management of these older patients. A large UK cohort study is currently underway to address this lack of evidence and to develop two DESIs to facilitate shared decision-making with older women about breast cancer treatments. Here, we present the development and initial testing of these two DESIs.
METHODS
METHODS
An initial prototype DESI was developed for the choice of primary endocrine therapy or surgery+endocrine therapy. Semi-structured interviews with healthy volunteers and patients explored DESI acceptability, usability, and utility. A framework approach was used for analysis. A second DESI for the choice of having chemotherapy or not was subsequently developed based on more focused development and testing.
RESULTS
RESULTS
Participants (n=22, aged 75-94 years, 64% healthy volunteers, 36% patients) found the primary endocrine therapy /surgery+endocrine therapy DESI acceptable, and contributed to improved wording and illustrations to address misunderstandings. The chemotherapy DESI (tested with 14 participants, aged 70-87 years, 57% healthy volunteers, 43% patients) was mostly understandable, however, suggestions for rewording sections were made. Most participants considered the DESIs helpful, but highlighted the importance of complementary discussions with clinicians.
CONCLUSION
CONCLUSIONS
It was possible to use a template DESI to efficiently create a second prototype for a different treatment option (chemotherapy). Both DESIs were acceptable and considered helpful to support/augment consultations. Development of acceptable additional DESIs for similar target populations using simplified methods may be an efficient way to develop future DESIs. Further research is needed to test the effectiveness of the DESIs.
Identifiants
pubmed: 30679905
doi: 10.2147/PPA.S178347
pii: ppa-13-131
pmc: PMC6338238
doi:
Types de publication
Journal Article
Langues
eng
Pagination
131-143Subventions
Organisme : Department of Health
ID : RP-PG-1209-10071
Pays : United Kingdom
Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
BMJ. 2000 Oct 21;321(7267):992-3
pubmed: 11039965
Br J Surg. 2003 Apr;90(4):388-99
pubmed: 12673739
Crit Rev Oncol Hematol. 2004 Jul;51(1):69-80
pubmed: 15207255
J Clin Oncol. 2005 Apr 20;23(12):2716-25
pubmed: 15837986
Eur J Oncol Nurs. 2006 Sep;10(4):263-72
pubmed: 16376146
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004272
pubmed: 16437480
Clin Oncol (R Coll Radiol). 2009 Mar;21(2):99-102
pubmed: 19200920
PLoS One. 2009;4(3):e4705
pubmed: 19259269
Lancet. 2012 Feb 4;379(9814):432-44
pubmed: 22152853
Patient Educ Couns. 2012 Aug;88(2):256-61
pubmed: 22465484
Lancet Oncol. 2012 Apr;13(4):e148-60
pubmed: 22469125
Ann Oncol. 2013 May;24(5):1211-9
pubmed: 23334117
Psychooncology. 2013 Dec;22(12):2729-35
pubmed: 23813806
Med Decis Making. 2014 Aug;34(6):699-710
pubmed: 23963501
Eur J Surg Oncol. 2014 Jun;40(6):676-84
pubmed: 24703110
Clin Oncol (R Coll Radiol). 2014 Nov;26(11):692-6
pubmed: 24909701
Psychooncology. 2015 Aug;24(8):878-84
pubmed: 25534045
Eur J Surg Oncol. 2015 May;41(5):607-9
pubmed: 25725950
BMC Med Inform Decis Mak. 2015 Jun 10;15:45
pubmed: 26058557
Br J Surg. 2015 Aug;102(9):1056-63
pubmed: 26095684
BMC Med Inform Decis Mak. 2016 Apr 21;16:45
pubmed: 27098100
Psychooncology. 2017 Dec;26(12):2094-2100
pubmed: 28332254
BMJ. 2017 Apr 18;357:j1744
pubmed: 28420639
BMJ Open. 2017 Jul 31;7(7):e015133
pubmed: 28760787